The JAK1 inhibitor in development for treating nonsegmental vitiligo was superior to placebo on investigator ratings in two phase 3 trials.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/upadacitinib-results-significant-improvements-nonsegmental-2026a10009j2?src=rss
Author :
Publish date : 2026-03-29 17:23:00
Copyright for syndicated content belongs to the linked Source.